Atara Biotherapeutics
ATRA
125 hedge funds and large institutions have $298M invested in Atara Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 22 closing their positions.
6,212% more call options, than puts
Call options by funds: $4.86M | Put options by funds: $77K
21% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 42
0.22% more ownership
Funds ownership: 4.07% → 4.28% (+0.22%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $316M → $298M (-$18.6M)
9% less funds holding
Funds holding: 138 → 125 (-13)
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$4.94M |
| 2 |
BG
Baupost Group
Boston,
Massachusetts
|
+$3.88M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.31M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.25M |
| 5 |
D.E. Shaw & Co
New York
|
+$2.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$2.45M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.97M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.51M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.38M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.2M |
ATRA Hedge Fund Activity: Q1 2023 in Review
125 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2023, worth a combined $298M — down 5.9% from $316M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ATRA and 9 opened new positions — a net loss of 13 holders — while 42 trimmed existing stakes and 51 added.
The largest buyer was Renaissance Technologies, adding an estimated $4.94M. The largest seller was Redmile Group, cutting an estimated $2.45M.
- 125 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2023, down from 138 in Q4 2022.
- Funds reported $298M of Atara Biotherapeutics stock for Q1 2023, down 5.9% quarter-over-quarter.
- 9 funds opened new Atara Biotherapeutics positions in Q1 2023 and 22 closed out, a net change of -13 holders.
- The largest Atara Biotherapeutics buyer in Q1 2023 was Renaissance Technologies, an estimated $4.94M added.
- The largest Atara Biotherapeutics seller in Q1 2023 was Redmile Group, an estimated $2.45M sold.
Based on aggregated 13F filings for Q1 2023.